These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 2785001

  • 1. Partial correction of defective generation of lymphokine-activated killer cells in patients with chronic myelogenous leukaemia after in vivo treatment with interferon-alpha (Wellferon).
    Pawelec G, Schneider E, Ehninger G, Rehbein A, Schmidt H.
    Cancer Immunol Immunother; 1989; 29(1):63-6. PubMed ID: 2785001
    [Abstract] [Full Text] [Related]

  • 2. Adherent lymphokine-activated killer cells in chronic myelogenous leukemia: a benign cell population with potent cytotoxic activity.
    Verfaillie C, Miller W, Kay N, McGlave P.
    Blood; 1989 Aug 01; 74(2):793-7. PubMed ID: 2473805
    [Abstract] [Full Text] [Related]

  • 3. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, gamma-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer-target binding and production of natural killer cytotoxic factor.
    Chang WC, Hsiao MH, Pattengale PK.
    Nat Immun Cell Growth Regul; 1991 Aug 01; 10(2):57-70. PubMed ID: 1881400
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
    Ellis TM, McKenzie RS, Simms PE, Helfrich BA, Fisher RI.
    J Immunol; 1989 Dec 15; 143(12):4282-6. PubMed ID: 2512355
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture.
    Cervantes F, Pierson BA, McGlave PB, Verfaillie CM, Miller JS.
    Blood; 1996 Mar 15; 87(6):2476-85. PubMed ID: 8630414
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cytotoxicity of interleukin 2-induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferons and tumor necrosis factor.
    Teichmann JV, Ludwig WD, Thiel E.
    Leuk Res; 1992 Mar 15; 16(3):287-98. PubMed ID: 1560676
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Generation of activated natural killer (A-NK) cells in patients with chronic myelogenous leukaemia and their role in the in vitro disappearance of BCR/abl-positive targets.
    Silla LM, Pincus SM, Locker JD, Glover J, Elder EM, Donnenberg AD, Nardi NB, Bryant J, Ball ED, Whiteside TL.
    Br J Haematol; 1996 May 15; 93(2):375-85. PubMed ID: 8639431
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of lymphokine-activated killer cell-mediated cytotoxicity by phorbol ester.
    Nishimura T, Burakoff SJ, Herrmann SH.
    J Immunol; 1989 Mar 15; 142(6):2155-61. PubMed ID: 2646377
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.